The second consecutive beat-and-raise quarter with accelerating innovation adoption and faster deleveraging supports a re-rating. Watch for Q3 guidance of $1.195B-$1.220B revenue and $0.19-$0.22 adjusted EPS, which implies a seasonal step-down but still strong YoY growth. The path to below 3x net leverage by year-end 2027 is a key catalyst for capital allocation flexibility.
ELAN drugs
ELAN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $26.22entry
- T+1 · 3mo ago −7.70%α −7.54% · $24.20
- T+5 · 3mo ago −15.95%α −16.30% · $22.04
- T+20 · 3mo ago −5.87%α −5.27% · $24.68
- T+60 · 19d ago −11.37%α −11.31% · $23.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs. the $0.27 consensus, on revenue of $1.368B (8% organic constant currency growth). The company raised full-year guidance across all key metrics, revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, and adjusted EPS to $1.10-$1.16, while improving its year-end net leverage target to ~3.0x. This marks a second consecutive beat-and-raise quarter, driven by accelerating innovation product adoption (Zenrelia, Credelio Quattro) and faster-than-expected margin expansion from the Elanco Ascend productivity program.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $1,368M, +10% reported YoY, +8% organic constant currency
- Adjusted EPS of $0.34 beat consensus of $0.27 by 26.5%
- Full-year 2026 guidance raised: revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, adjusted EPS to $1.10-$1.16
- Net leverage ratio improved to 3.1x at quarter-end, down from 3.5x at Q1 end and 3.6x at Dec 2025
- Innovation revenue target raised to $1.25B; Zenrelia achieved blockbuster status, Credelio Quattro penetrated >50% of U.S. clinic base
- Operating cash flow of $277M in Q2 vs $237M in prior year; adjusted gross margin expanded 80bps to 58.1%
Financial Impact
Q2 revenue $1.368B, adjusted EPS $0.34; full-year guidance raised by ~$70M at midpoint on revenue and ~$0.07 on adjusted EPS
Risk Factors
- Q3 guidance implies a sequential revenue decline of ~11% from Q2, reflecting normal seasonality in animal health
- Operating expenses up ~10% YoY in constant currency for Q3, pressuring near-term margins
- Swine revenue declined 4% YoY on an organic constant currency basis, a potential headwind if pork demand softens
- Integration of AHV International acquisition adds execution risk
- Substantial debt load ($3.16B net debt) limits financial flexibility despite deleveraging progress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001739104-26-000040 |
| Document: elan-20260805.htm | 0001739104-26-000040 |
| Document: 0001739104-26-000040-index-headers.html | 0001739104-26-000040 |
| Document: 0001739104-26-000040-index.html | 0001739104-26-000040 |
| Document: 0001739104-26-000040.txt | 0001739104-26-000040 |
| 8-K Data (Synthetic) | 0001739104-26-000040 |
Track record
19 reports on ELAN
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers